RT Journal Article
T1 Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease.
A1 Mena-Vazquez, Natalia
A1 Rojas-Gimenez, Marta
A1 Fuego-Varela, Clara
A1 Garcia-Studer, Aimara
A1 Perez-Gomez, Nair
A1 Romero-Barco, Carmen Maria
A1 Godoy-Navarrete, Francisco Javier
A1 Manrique-Arija, Sara
A1 Gandia-Marinez, Myriam
A1 Calvo-Gutierrez, Jerusalem
A1 Morales-Garrido, Pilar
A1 Mouriño-Rodriguez, Coral
A1 Castro-Perez, Patricia
A1 Añon-Oñate, Isabel
A1 Espildora, Francisco
A1 Aguilar-Hurtado, Maria Carmen
A1 Hidalgo-Conde, Ana
A1 Arnedo-Diez de-Los-Rios, Rocio
A1 Cabrera-Cesar, Eva
A1 Redondo-Rodriguez, Rocio
A1 Velloso-Feijoo, Maria Luisa
A1 Fernandez-Nebro, Antonio
K1 Abatacept
K1 Biologics
K1 Interstitial lung disease
K1 Rheumatoid arthritis
K1 AGS - Jerez, Costa Noroeste y Sierra de Cádiz
K1 AGS - Sur de Sevilla
AB To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2-42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03-3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70-0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72-0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.
PB MDPI
SN 2227-9059
YR 2022
FD 2022-06-22
LK http://hdl.handle.net/10668/20838
UL http://hdl.handle.net/10668/20838
LA en
NO Mena-Vázquez N, Rojas-Gimenez M, Fuego-Varela C, García-Studer A, Perez-Gómez N, Romero-Barco CM, et al. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease. Biomedicines. 2022 Jun 22;10(7):1480
DS RISalud
RD Apr 9, 2025